31 62

Cited 0 times in

Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review

DC Field Value Language
dc.contributor.author구교철-
dc.date.accessioned2021-09-29T00:55:13Z-
dc.date.available2021-09-29T00:55:13Z-
dc.date.issued2021-05-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/184105-
dc.description.abstractRenal cell carcinoma (RCC) is a malignant tumor associated with various tumor microenvironments (TMEs). The immune system is activated by the development of cancer and drives T cell anti-tumor response. CD8 T cells are known to improve clinical outcomes and sensitivity to immunotherapy, and play a crucial role against tumors. In contrast, tumor-associated macrophages (TAMs) suppress immunity against malignancy and lead to tumor progression. TAMs are promoted from damaged TMEs and mount proinflammatory responses to pathogens. Initial immunotherapy consists of interferon-α and interleukin-2. However, response to such therapy is unclear in most patients, and it is associated with high levels of toxicity. Immune checkpoint inhibitors (ICIs), which up-regulate immune responses by blocking the programed cell death protein 1 (PD-1) receptor, the ligand of PD-1, or cytotoxic T-lymphocyte-associated protein 4 T cells, have led to a new era of immunotherapy. Furthermore, combination strategies with ICIs have proven effective through several randomized controlled trials. We expect the next generation of immunotherapy to lead to better outcomes based on ongoing trials and inspire new therapeutic strategies.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI-
dc.relation.isPartOfINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAnimals-
dc.subject.MESHCarcinoma, Renal Cell / immunology-
dc.subject.MESHCarcinoma, Renal Cell / pathology-
dc.subject.MESHCarcinoma, Renal Cell / therapy*-
dc.subject.MESHHumans-
dc.subject.MESHImmunotherapy / methods*-
dc.subject.MESHKidney Neoplasms / immunology-
dc.subject.MESHKidney Neoplasms / pathology-
dc.subject.MESHKidney Neoplasms / therapy*-
dc.subject.MESHTumor Microenvironment / immunology*-
dc.titleImmunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorYoon-Soo Hah-
dc.contributor.googleauthorKyo-Chul Koo-
dc.identifier.doi10.3390/ijms22094452-
dc.contributor.localIdA00188-
dc.relation.journalcodeJ01133-
dc.identifier.eissn1422-0067-
dc.identifier.pmid33923219-
dc.subject.keywordbiomarkers-
dc.subject.keywordclinical trials-
dc.subject.keywordimmune checkpoint inhibitor-
dc.subject.keywordimmunotherapy-
dc.subject.keywordrenal cell carcinoma-
dc.contributor.alternativeNameKoo, Kyo Chul-
dc.contributor.affiliatedAuthor구교철-
dc.citation.volume22-
dc.citation.number9-
dc.citation.startPage4452-
dc.identifier.bibliographicCitationINTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, Vol.22(9) : 4452, 2021-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.